2024. Bimekizumab Efficacy through Year 1 in Patients with Moderate to Severe Plaque Psoriasis Who Had Not Achieved a PASI 90 Response by Week 16: A Pooled Analysis from Four Phase 3/3B Trials. SKIN The Journal of Cutaneous Medicine. 8, 2 (Mar. 2024), s369. DOI:https://doi.org/10.25251/skin.8.supp.369.